Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 February 2018

Khomotso matriculated in Lephalale in Limpopo and made her way to Bloemfontein in January 2014. She was determined to succeed in life and knew that she had one chance to achieve her objective, which was to obtain a degree. However, coming from a family with an annual income of less than R80 000 she knew she would have to find funding. She secured a bursary with Distell, although it would only cover her tuition, so her next challenge was finding funding for meals and other expenses.

Making a difference daily
When she arrived at the University of Free State (UFS) she applied for the No Student Hungry (NSH) Food Bursary through the Social Work Services office and was successful. The weekly NSH funds she received enabled her to buy food and offered her extra opportunities to develop herself through student wellness workshops. NSH funded her for the next three years. “It was a relief not to worry about where my next meal would come from, allowing me time to concentrate on my studies,” said Khomotso.

Three years later she graduated with 22 distinctions and is pursuing her postgraduate studies in Education in 2018. For her, it is important to create the change that our country needs. “It was my teachers and parents who inspired me to pursue a degree. As a future teacher, I want to be able to make a difference in the lives of young people. “

Donors key in reducing food insecurity
Like Khomotso, there are many academically strong students who lack adequate financial support to sustain them through their degree programmes. For this reason, the financial contributions made to the NSH Food Bursary Programme by staff of the UFS, alumni and other donors remains crucial. Systemic change occurs when students graduate and join the country’s workforce. Together, we continue to cause ripples of change in our country.

The South African Surveys of Student Engagement Annual Report (2016)
reflects that “it is clear that financial stress impacts on different areas of students’ lives. It is also clear that the impact is magnified for those who are already vulnerable, such as students who come from poor families”.

No Student Hungry supports students on their journey to success

Figure 7 shows that 32% of black African students reported that they ran out of food and could not afford to buy more on most days or every day. Similarly, a significant difference in responses is seen between first- and non-first-generation students, with 77% of first-generation students indicating that they ran out of food without being able to buy more, compared to 53% of non-first-generation students.

The overall academic average of 2017 NSH students was 61% on all three UFS campuses, with the top 10 achievers of 2017 being females predominantly in the black African and coloured designated groups, in the fields of Communication, Law, Education, Science, Social Science and Psychology, scoring on average above 70%.

Give to the NSH Food Bursary.

Contact: Vicky Simpson, Officer Institutional Advancement SimpsonVZ@ufs.ac.za /call: +27 51 401 7197.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept